Health
Bharat Biotechs Covaxin succeeds in challenge trials on Rhesus monkeys – Business Standard
The results showed protective efficacacy, increasing Sars-CoV-2 specific IgG and neutralising antibodies reducing the replication of the virus in the nasal cavity, throat and lung tissues of monkey

Hyderabad-based Bharat Biotech has released the data from the animal trials of its vaccine candidate, which showed that Covaxin was able to generate ‘robust immune responses’.
The firm said that the vaccine prevented infection and disease in the primates upon high amounts of exposure to live virus Sars-CoV-2. This is called a challenge trial where a participant is exposed deliberately to the pathogen after being given the vaccine shot.
The company tweeted “Bharat Biotech proudly announces th…
-
Noosa News7 hours ago
How Lily Steele-Park took her rapist to court and won
-
General21 hours ago
‘Potential’ hacker contacts Qantas over data breach
-
Business12 hours ago
Ford CEO makes stunning prediction about artificial intelligence
-
Noosa News10 hours ago
Star’s Brisbane casino has been in the headlines for months: What’s the latest?